HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berahovich, R. D. Articles by Schall, T. J. Search for Related Content PubMed PubMed Citation Articles by Berahovich, R. D. Articles by Schall, T. J.

Proteolytic Activation of Alternative CCR1 Ligands in Inflammation¹

ChemoCentryx, Mountain View, CA 94043

Although chemokines CCL3/MIP-1 and CCL5/RANTES are considered to be primary CCR1 ligands in inflammatory responses, alternative CCR1 ligands have also been described. Indeed, four such chemokines, CCL6/C10/MIP-related protein-1, CCL9/MIP-1/MIP-related protein-2, CCL15/MIP-1/hemofiltrate CC chemokine-2/leukotactin-1, and CCL23/CK8/myeloid progenitor inhibitory factor-1, are unique in possessing a separately encoded N-terminal domain of 16–20 residues and two additional precisely positioned cysteines that form a third disulfide bridge. In vitro, these four chemokines are weak CCR1 agonists, but potency can be increased up to 1000-fold by engineered or expression-associated N-terminal truncations. We examined the ability of proinflammatory proteases, human cell supernatants, or physiological fluids to perform N-terminal truncations of these chemokines and thereby activate their functions. Remarkably, most of the proteases and fluids removed the N-terminal domains from all four chemokines, but were relatively unable to cleave the truncated forms further. The truncated chemokines exhibited up to 1000-fold increases in CCR1-mediated signaling and chemotaxis assays in vitro. In addition, N-terminally truncated CCL15/MIP-1 and CCL23/CK8, but not CCL3/MIP-1 or CCL5/RANTES, were detected at relatively high levels in synovial fluids from rheumatoid arthritis patients. These data suggest that alternative CCR1 ligands are converted into potent chemoattractants by proteases released during inflammatory responses in vivo.

This article has been cited by other articles:

				Z. Miao, B. A. Premack, Z. Wei, Y. Wang, C. Gerard, H. Showell, M. Howard, T. J. Schall, and R. Berahovich Proinflammatory Proteases Liberate a Discrete High-Affinity Functional FPRL1 (CCR12) Ligand from CCL23 J. Immunol., June 1, 2007; 178(11): 7395 - 7404. [Abstract] [Full Text] [PDF]

				N. Shimoda, N. Fukazawa, K. Nonomura, and R. L. Fairchild Cathepsin G Is Required for Sustained Inflammation and Tissue Injury after Reperfusion of Ischemic Kidneys Am. J. Pathol., March 1, 2007; 170(3): 930 - 940. [Abstract] [Full Text] [PDF]